The NICHE-2 study offered neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer patients, resulting in a major pathologic response in 95% of patients and 67% pCR. In discussion with the lead author, Dr. Myriam Chalabi - Medical Oncologist at the Netherlands Cancer Institute.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
